Biogen to expand access to its ALS drug, but move may come too late for some patients

first_img After weeks of controversy, Biogen (BIIB) has agreed to provide an experimental drug for combating ALS to a small group of very sick patients under a so-called expanded access program. But the move may come too late for the woman who pushed the company to take this step.The decision follows sustained pressure by ALS patients, notably Lisa Stockman Mauriello, a health care communications executive who has a rare and fast-moving form of the neurological disease. This subset of patients typically has a very short life span, but no treatment options. So with help from supporters, she mounted a high-profile campaign to convince Biogen to provide access to its drug as quickly as possible. What’s included? Pharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What is it? By Ed Silverman April 27, 2021 Reprints Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. About the Author Reprints Ed Silvermancenter_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Lisa Stockman Mauriello, who was diagnosed with ALS, with her husband and children. Courtesy Lisa Stockman Mauriello Log In | Learn More GET STARTED @Pharmalot Biogen to expand access to its ALS drug, but move may come too late for some patients [email protected] Tags clinical trialsdrug developmentneurologylast_img

Leave a Reply

Your email address will not be published. Required fields are marked *